Notably, TNF‐α antagonists like infliximab have been tested in depression: a randomized controlled trial found that while infliximab overall did not outperform placebo, it significantly improved mood symptoms in the high baseline inflammation subgroup (CRP > 5 mg/L) [693]. The gene discussed is CRP; the disease is major depressive disorder.